KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $2.2 billion.

  • Teva Pharmaceutical Industries' Cash & Current Investments fell 33.62% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 billion, marking a year-over-year decrease of 20.63%. This contributed to the annual value of $3.3 billion for FY2024, which is 2.29% up from last year.
  • According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' Cash & Current Investments is $2.2 billion, which was up 1.94% from $2.2 billion recorded in Q2 2025.
  • Teva Pharmaceutical Industries' 5-year Cash & Current Investments high stood at $3.3 billion for Q3 2024, and its period low was $1.7 billion during Q1 2025.
  • Its 3-year average for Cash & Current Investments is $2.6 billion, with a median of $2.3 billion in 2024.
  • In the last 5 years, Teva Pharmaceutical Industries' Cash & Current Investments surged by 47.58% in 2024 and then slumped by 43.26% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Cash & Current Investments (Quarterly) stood at $2.2 billion in 2021, then climbed by 29.38% to $2.8 billion in 2022, then climbed by 15.17% to $3.2 billion in 2023, then grew by 2.29% to $3.3 billion in 2024, then plummeted by 33.62% to $2.2 billion in 2025.
  • Its Cash & Current Investments was $2.2 billion in Q3 2025, compared to $2.2 billion in Q2 2025 and $1.7 billion in Q1 2025.